SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Energy Transfer LP engages in natural gas pipeline transportation and transmission services. It operates through the following segments: Intrastate Transportation and Storage, Interstate Transportation and Storage, Midstream, NGL and Refined Products Transportation and Services, Crude Oil Transportation and Services, Investment in Sunoco LP, Investment in USAC, and All Other. The Intrastate Transportation and Storage segment owns and operates natural gas transportation pipelines. The Interstate Transportation and Storage segment includes transportation pipelines, storage facilities, and gathering systems and delivery of natural gas to industrial end-users and other pipelines. The Midstream segment consists of natural gas gathering, compression, treating, processing, storage, and transportation. The NGL and Refined Products Transportation segment engages in the operations transport, store and execute acquisition, and marketing activities utilizing a complementary network of pipelines, storage and blending facilities, and strategic off-take locations that provide access to multiple NGL markets. The Crude Oil Transportation and Services segment provides transportation, terminalling, acquisition, and marketing services to crude oil markets. The Investment in Sunoco LP segment refers to the distribution of motor fuels to independent dealers, distributors, and other commercial customers and the distribution of motor fuels to end-user customers at retail sites. The Investment in USAC segment offers compression services to its customers in connection with infrastructure applications including both allowing for the processing and transportation of natural gas through the domestic pipeline system and enhancing crude oil production through artificial lift processes. The company was founded by Kelcy L. Warren in 1996 and is headquartered in Dallas, TX.

Energy Transfer LP - Unit

Energy Transfer LP Unit

ETs recent weakness is being debated after a reported quarterly earnings miss, despite higher full-year EBITDA guidance; traders also point to interest-rate concerns, election uncertainty, and questions about whether NGL profits will repeat. Some investors view the pullback as a buying opportunity, citing the distribution and potential data-center gas demand, though several prospective contracts remain unconfirmed.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLakes sonelokimab BLA for hidradenitis suppurativa and the pending FDA decision on whether to accept it for review are the main focus, with traders also debating whether the FDA will grant priority review. Bullish posters point to the drugs clinical data and potential acquisition interest, while skeptics highlight regulatory and competitive risks, plus concerns that MoonLake may commercialize on its own and need more financing.

Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib, which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia, KO-947, which is an ERK inhibitor for MAPK Pathway Tumors, and KO-539, which is a Menin MLL inhibitor for acute leukemias. The company was founded by Troy E. Wilson, Yi Liu, Pingda Ren and Antonio Gualberto on August 22, 2014 and is headquartered in San Diego, CA.

Kura Oncology Inc

Competitive J&J bleximenib data has raised concern about future share for Kuras menin inhibitor, with traders debating whether differences in prior venetoclax exposure make the comparison misleading. Some view the selloff as an overreaction and are looking to ASH data for clearer evidence on ziftomenibs frontline potential.

ProShares Trust II - ProShares UltraShort Bloomberg Crude Oil -2x Shares

ProShares UltraShort Bloomberg Crude Oil

Traders are using SCO to bet on falling crude amid volatile Iran-conflict and Strait of Hormuz headlines, weighing escalation-driven supply risks against hopes for a deal and restored oil flows. Many also complain that the fund has lagged oils declines, while others point to daily-reset compounding and futures-market backwardation as reasons its returns can diverge from expectations.

Victoria's Secret & Co. operates as a lingerie, clothing and beauty retailer. It offers bras, panties, lingerie, sleepwear, apparel, sport and swim apparel, and beauty products. The company was founded in 1963 and is headquartered in Reynoldsburg, OH.

Victoria`s Secret & Co

Victorias Secrets turnaround momentum and strong earnings-driven rally, alongside analyst upgrades, are fueling bullish interest and technical-breakout chatter. Traders remain divided, with some citing improving brand demand and guidance while skeptics warn the run-up may be overextended and vulnerable to a pullback.

Berkshire Hathaway, Inc. is a holding company, which engages in the provision of property and casualty insurance and reinsurance, utilities and energy, freight rail transportation, finance, manufacturing, and retailing services. It operates through the following segments: Insurance, Burlington Northern Santa Fe, LLC (BNSF), Berkshire Hathaway Energy (BHE), Pilot Travel Centers (PTC), Manufacturing, McLane, and Service and Retailing. The Insurance segment includes the underwriting of GEICO, Berkshire Hathaway Primary Group, and Berkshire Hathaway Reinsurance Group. The BNSF segment involves the operation of railroad systems. The BHE segment focuses on regulated electric and gas utility, power generation and distribution, and real estate brokerage activities. The PTC segment consists of managing travel centers and marketing of wholesale fuel. The Manufacturing segment refers to industrial, consumer and building products, home building, and related financial services. The McLane segment covers the wholesale distribution of groceries and non-food items. The Service and Retailing segment relates to the provision of shared aircraft ownership programs, aviation pilot training, electronic components distribution, retailing businesses, automobile dealerships and trailer, and furniture leasing services. The company was founded by Oliver Chace in 1839 and is headquartered in Omaha, NE.

Berkshire Hathaway Inc. - Ordinary Shares - Class B

Berkshires Q3 results are drawing attention, with weaker operating performanceparticularly in insuranceset against a sharp increase in share repurchases. Traders are split between concern over the earnings softness and approval of the buybacks as a sign of management confidence and disciplined capital allocation.

Chevron Corp. engages in the provision of oil and gas energy solutions. It provides crude oil and natural gas, manufactures transportation fuels, lubricants, petrochemicals, and additives, and develops technologies that enhance business and the industry. It operates through the Upstream and Downstream segments. The Upstream segment consists of the exploration, development, and production of crude oil and natural gas, the liquefaction, transportation, and regasification associated with liquefied natural gas, the transporting of crude oil by major international oil export pipelines, the processing, transporting, storage, and marketing of natural gas, and a gas-to-liquids plant. The Downstream segment consists of the refining of crude oil into petroleum products, the marketing of crude oil and refined products, the transporting of crude oil and refined products by pipeline, marine vessel, motor equipment, and rail car, and the manufacturing and marketing of commodity petrochemicals and plastics for industrial uses and fuel & lubricant additives. The company was founded on September 10, 1879 and is headquartered in Houston, TX.

Chevron Corp.

Chevrons stronger-than-expected Q3 results, driven in part by elevated diesel refining margins and record U.S. refinery throughput, are the main focus. Traders are highlighting the cash generation and debt reduction, while debating whether the earnings strength can last and whether the recent pullback signals profit-taking.

BlackRock, Inc. engages in the provision of investment, advisory, and risk management solutions. Its products include single-asset and multi-asset portfolios. The company was founded by Laurence Douglas Fink and Robert Steven Kapito in 1988 and is headquartered in New York, NY.

Blackrock Inc.

BlackRocks strong quarterly results and record asset inflows are driving attention, with traders highlighting the earnings beat and renewed share strength. The bullish reaction is tempered by concerns that BlackRock-managed funds and financing are heavily exposed to AI infrastructure and concentrated index holdings.

Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip Astley-Sparke, Colin A. Love, and Robert Coffin in March 2015 and is headquartered in Woburn, MA.

Replimune Group Inc

Replimunes FDA accelerated approval of Tudriqev and subsequent equity financing are driving attention, with traders debating whether the new capital supports commercialization or signals further dilution. Bulls point to institutional demand and short covering, while bears remain focused on cash burn, the required confirmatory trial, and uncertain commercial uptake.

Pepe (PEPE) is a cryptocurrency launched in 2023and operates on the Ethereum platform. Pepe has a current supply of 413,772,350,098,130.40630647. The last known price of Pepe is 0.00000498 USD and is up 2.29 over the last 24 hours. It is currently trading on 729 active market(s) with $440,504,313.03 traded over the last 24 hours. More information can be found at https://www.pepe.vip/.

Pepe

PEPE is drawing attention for volatile swings around the 0.000005 level, with traders watching whether it can break and hold above resistance after repeated pullbacks. Dip buyers expect a renewed meme-coin rally, while skeptics view the bounces as temporary and point to weak price action and broader crypto-market pressure.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Here's What Key Metrics Tell Us About Mirum Pharmaceuticals (MIRM) Q3 Earnings

While the top- and bottom-line numbers for Mirum Pharmaceuticals (MIRM) give a sense of how the business performed in the quarter ended September 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Mirum Pharmaceuticals, Inc. (MIRM) Reports Q3 Loss, Tops Revenue Estimates

Mirum Pharmaceuticals (MIRM) delivered earnings and revenue surprises of -64.15% and +5.25%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

Mirum Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today reported financial results for the third quarter 2026 and provided a business update. The third quarter was an important period of execution for Mirum, with the approval and launch of ATEBRIOZ and positive Phase 3...

Mirum Pharmaceuticals Showcases Momentum Across Rare Liver Disease Portfolio with New Data at AASLDs The Liver Meeting 2026

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced that data from its rare liver disease portfolio will be presented at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting 2026, taking place November 5-9, 2026, in Denver...

Recursion Pharmaceuticals (RXRX) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

Recursion Pharmaceuticals (RXRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Mirum Pharmaceuticals to Announce Third Quarter 2026 Financial Results and Host Conference Call on November 3, 2026

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced that it will report third quarter 2026 financial results on November 3, 2026. Mirum will also host a conference call to discuss the third quarter 2026 financial results and recent corporate progress...

Mirum Pharmaceuticals, Inc. (MIRM) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

Mirum Pharmaceuticals (MIRM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Mirum Pharmaceuticals Announces Positive Results from Cohort 2 of the Pivotal PROGRESS Study of ATEBRIOZ (zilurgisertib) in Pediatric Patients Aged 6 to

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM), a leading rare disease company, today announced positive results from Cohort 2 of the pivotal PROGRESS study of ATEBRIOZ (zilurgisertib), an oral activin receptor-like kinase 2 (ALK2) inhibitor, in pediatric patients aged 6 to &lt;12 years with...

Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced that it will participate in the following upcoming investor conferences: Wolfe Research Healthcare Conference 2026: Tuesday, November 10, 2026 Company fireside chat starting at 8:00 a.m. ET Stifel 2026...

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced that on October 9, 2026, the Compensation Committee of Mirums Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 18,663 shares of common stock and 24,687...

• Reported GAAP EPS of -$0.87 down -1840.00% YoY
• Reported revenue of $185.72M up 39.63% YoY
• Mirum expects total product sales of approved medicines to continue to increase on an annual basis and anticipates net losses for the foreseeable future; no quantified financial range was provided.

Mirum swung to a quarterly net loss amid higher operating expenses; FDA recommended a Phase 3 volixibat study delaying the NDA timeline; generic LIVMARLI applicants challenge patents through ongoing litigation.

Mirum's product sales rose versus Q3 2025; EXPAND showed statistically significant pruritus improvement; AZURE-1 met its primary endpoint, and FDA approved Atebrioz for FOP treatment.

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The firm focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. Its products pipeline includes Maralixibat, Cholbam, Ctexli, Volixibat, Brelovitug, MRM-3379, and Zilurgisertib. The company was founded by Niall O'Donnel, Michael G. Grey, and Christopher Peetz in May 2018 and is headquartered in Foster City, CA.

Mirum Pharmaceuticals Inc

FDA Decision Watch: BMY, EGTX Face Key Decisions This Week As BFRI, SRRK And MIRM Score Early Approvals

Equity

Bullish Sentiment

<ul class="summary-bullets"><li>Bristol Myers Squibb faces an FDA decision on Sept. 30 for expanding Camzyos to adolescents with obstructive hypertrophic cardiomyopathy.</li><li>Scholar Rock’s Isembyld and Biofrontera's (BFRI) Ameluz received FDA clearance ahead of their scheduled late-September PDUFA dates.</li><li>Mirum Pharmaceuticals’ Atebrioz got FDA approval on Friday for patients aged 12-18 with an ultra-rare genetic disease.</li></ul>Biotech and pharmaceutical investors have key U.S. Food and Drug Administration (FDA) events to watch this week, including decisions on treatments for a rare genetic disorder and a heart condition, while several other drugs originally scheduled for late-September decisions have already received regulatory clearance.Bristol Myers Squibb (<a class="mention" data-mention="$BMY" data-symbol-id="BMY" href="https://stocktwits.com/symbol/BMY" target="_blank">BMY</a>) awaits an FDA decision on expanding Camzyos to adolescents with obstructive hypertrophic cardiomyopathy, a condition in which thickened heart muscle blocks blood flow. Stockholm-listed Egetis Therapeutics also faces a decision on Emcitate for MCT8 deficiency, a rare genetic disorder that affects how thyroid hormones reach the brain and other tissues.Meanwhile, Biofrontera (BFRI) and Scholar Rock (SRRK) entered the week with decisions originally scheduled for this period, while Mirum Pharmaceuticals (MIRM) and Incyte (INCY) received FDA approval for Atebrioz late last week.A PDUFA date is the target deadline by which the FDA aims to complete its review of a drug application.<img src="https://news.stocktwits-cdn.com/4_Hpst_fda_decisions_this_week_1_7833148823.png" alt="4Hpst-fda-decisions-this-week- (1).png"><h2 class="st-heading-2">Bristol Myers Awaits Camzyos Label Expansion</h2>The FDA is scheduled to make a decision on Bristol Myers Squibb (<a class="mention" data-mention="$BMY" data-symbol-id="BMY" href="https://stocktwits.com/symbol/BMY" target="_blank">BMY</a>) on September 30. The regulatory body will decide whether to expand the use of Camzyos (Mavacamten) to adolescents ages 12 to under 18 with symptomatic obstructive hypertrophic cardiomyopathy (oHCM).Obstructive HCM is a condition in which the heart muscle becomes abnormally thick, potentially blocking blood flow out of the heart. Patients can experience shortness of breath, fatigue and chest pain.Camzyos is already FDA-approved for certain adults with symptomatic oHCM. Bristol Myers said the safety profile among adolescents was similar to that previously observed in adults.If cleared, Camzyos would become the first cardiac myosin inhibitor approved in the U.S. for adolescents with oHCM, according to the company.<h2 class="st-heading-2">Egetis Awaits FDA Decision On Rare Genetic Disorder Drug</h2>Egetis Therapeutics faces a September 28 decision on Emcitate for MCT8 deficiency.If approved, Emcitate would become the first FDA-approved treatment for MCT8 deficiency in the U.S. The drug is already approved in the European Union, and the FDA has already granted the application Priority Review. Emcitate has also received Breakthrough Therapy, Orphan Drug and Rare Pediatric Disease designations from the FDA.<h2 class="st-heading-2">FDA Already Acted On Several Late-September Decisions</h2>Several other drugs that had been heading toward FDA decisions around this week have already received regulatory clearance.Scholar Rock’s (SRRK) Isembyld was scheduled for a September 30 PDUFA date, but the FDA approved the treatment on Sept. 11 for adults and children aged two years and older with spinal muscular atrophy who are already receiving an SMN2-targeted treatment.Spinal muscular atrophy is a rare genetic disease that causes progressive muscle weakness and loss of motor function. Scholar Rock said Isembyld is the first and only muscle-targeted treatment approved for SMA. However, SRRK shares are down more than 12% since the approval.Biofrontera’s (BFRI) Ameluz also received an FDA decision ahead of its September 28 PDUFA date. The label expansion covers Ameluz photodynamic therapy for superficial basal cell carcinoma, a common form of skin cancer. BFRI shares have seen an even sharper decline, down 23% since the FDA decision on September 14.<h2 class="st-heading-2">Mirum Gets FOP Drug Approval</h2>On Friday, the FDA approved Mirum Pharmaceuticals’ (MIRM) Atebrioz for patients aged 12 and older with fibrodysplasia ossificans progressiva (FOP), an ultra-rare genetic disease that causes bone to form in muscles and other soft tissues, gradually restricting movement.Mirum expects Atebrioz to become available in the U.S. in October.The biotech firm acquired worldwide rights to Atebrioz from Incyte (INCY) earlier this year. Incyte remains eligible for milestone payments and royalties from the drug.MIRM shares closed Friday’s session 0.4% higher and are currently trading up 3% in pre-market.<h2 class="st-heading-2">How Have BFRI, <a class="mention" data-mention="$BMY" data-symbol-id="BMY" href="https://stocktwits.com/symbol/BMY" target="_blank">BMY</a>, SRRK, MIRM And INCY Performed YTD?</h2><img src="https://news.stocktwits-cdn.com/Biotech_63ba5c5882.png" alt="Biotech.png">Among these stocks, Biofrontera (BFRI) has gained the most this year, rising nearly 63%, followed by Incyte (INCY) at more than 22% and Bristol Myers Squibb (<a class="mention" data-mention="$BMY" data-symbol-id="BMY" href="https://stocktwits.com/symbol/BMY" target="_blank">BMY</a>) at about 18%. Scholar Rock (SRRK) and Mirum Pharmaceuticals (MIRM) have each gained roughly 13%.Also read:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/critical-minerals-wrap-crml-grml-surge-on-greenland-deal-us-stockpile-push-accelerates-as-trump-xi-talks-put-rare-earths-in-spotlight/cZMg2lHRBOY">Critical Minerals Wrap: CRML, GRML Surge On Greenland Deal, US Stockpile Push Accelerates As Trump-Xi Talks Put Rare Earths In Spotlight</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

 In this photo illustration, the United States Food and Drug Administration (FDA) logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Biotech and pharmaceutical investors have key U.S. Food and Drug Administration (FDA) events to watch this week, including decisions on treatments for a rare genetic disorder and a heart condition, while several other drugs originally scheduled for late-S

FDA Decision Watch: BMY, EGTX Await Key Rulings As BFRI, SRRK, MIRM Win Early Approvals 

Bristol Myers Squibb and Egetis await FDA decisions on treatments for heart and rare genetic conditions, while Scholar Rock, Biofrontera and Mirum have already secured regulatory wins ahead of schedule.


Biofrontera Inc

Bristol-Myers Squibb Co.

Incyte Corp.

Scholar Rock Holding Corp

SPDR S&P Biotech ETF

Up more than 1% 

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Current Price	$93.72
Prev Close	$93.54
Open	$93.14
Dividend Yield	0.00%
50-Day Moving Average	$89.29
Beta	0.89
Avg. Volume	747,551.04
PE Ratio	-6.16

52-Week High	$130.00
52-Week Low	$63.23
Market Capitalization	$6.12B
EPS (Annual)	-$0.4654
Price to Book	-112.79
Revenue Per Employee	$1.4M

Feed

News

Sentiment

Earnings

Fundamentals

Info

MIRM Fundamentals